PURPOSE: Biomarkers are valuable tools for predicting mortality in patient with sepsis. However, the use of a single biomarker to predict patient outcome is challenging due to the complexity and redundancy of the immune response to infection. We aim...
PURPOSE: Biomarkers are valuable tools for predicting mortality in patient with sepsis. However, the use of a single biomarker to predict patient outcome is challenging due to the complexity and redundancy of the immune response to infection. We aimed to conduct a prospective observational analysis to investigate the prognostic value (predicting the 28-day mortality) of a combination of lactate, procalcitonin, pentraxin 3, and interleukin 6 in patients with sepsis and septic shock (n = 160; sepsis, 78; sepsis shock, 82).
METHODS: Two methods (the frequency sum of values above the cut-off and a multivariate logistic regression model) were used to assess the prognostic value of the biomarker combination.
RESULTS: In a receiver operating characteristic (ROC) curve analysis using the frequency sum of values above the cut-off, the combination of the four biomarkers predicted the 28-day mortality better than the Sequential Organ Failure Assessment (SOFA) score and each individual biomarker. Similarly, in the ROC curve analysis using a multivariate logistic model, the biomarker combination predicted the 28-day mortality better than the SOFA score and each individual biomarker.
CONCLUSION: The combined biomarker approach showed good performance in predicting the all-cause 28-day mortality among patients with sepsis and septic shock diagnosed according to the Sepsis-3 definitions. Furthermore, it can be used to supplement the SOFA score for predicting mortality.